Boston Scientific’s BSX fourth-quarter 2024 performance was driven by its robust expansion of operations across different geographies outside the United States. The company’s impressive strategic ...

In a wide manufacturing room with white walls and low ceilings, Boston Scientific employees combine components into finished ...

Boston Scientific has shown high revenue and EPS growth rates in recent years. See why I recommend a hold rating for BSX ...

In this photo illustration, the Boston Scientific company logo is seen ... [+] displayed on a smartphone screen. (Photo ...

Use of two high-risk cardiovascular devices—the Watchman (Boston Scientific) left atrial appendage occluder and the Impella (Abiomed) left ventricular assist device—is highest in the United States ...

Boston Scientific Corporation develops ... and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices ...

Boston Scientific Corporation BSX ... In Japan, strong contributions from AGENT DCB, Rezum, WATCHMAN FLEX Pro and a very early contribution from FARAPULSE drove growth. The company recognized ...

Boston Scientific’s product portfolio is a key driver of its success, with several standout offerings contributing to its strong market position. The Farapulse and Watchman products have shown ...

The long-term prospects of the WATCHMAN devices are also encouraging. Meanwhile, headwinds like currency fluctuations pose a concern for Boston Scientific’s operations. In the past year ...